Interventions for hidradenitis suppurativa

Ingram, John R. ORCID: https://orcid.org/0000-0002-5257-1142 2017. Interventions for hidradenitis suppurativa. JAMA Dermatology 153 (5) , pp. 458-459. 10.1001/jamadermatol.2017.0432

Full text not available from this repository.

Abstract

Clinical Question: Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults? Bottom Line: There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, −3.7 to −2.0 points) and 1.6 points (95% CI, −3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Medical Association
ISSN:	2168-6068
Last Modified:	21 Oct 2022 07:41
URI:	https://orca.cardiff.ac.uk/id/eprint/100492

Citation Data

Cited 26 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item